Russell Investments Group Ltd. Cuts Stock Holdings in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)

Russell Investments Group Ltd. lowered its stake in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 28.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,000 shares of the company’s stock after selling 6,400 shares during the quarter. Russell Investments Group Ltd.’s holdings in Amphastar Pharmaceuticals were worth $317,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 1.5% during the second quarter. BlackRock Inc. now owns 5,927,141 shares of the company’s stock worth $125,124,000 after buying an additional 87,107 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 2.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,381,761 shares of the company’s stock valued at $50,279,000 after purchasing an additional 57,349 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 33.2% in the 2nd quarter. Renaissance Technologies LLC now owns 588,000 shares of the company’s stock valued at $12,413,000 after purchasing an additional 146,400 shares during the last quarter. Nuveen Asset Management LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at $12,134,000. Finally, Northern Trust Corp boosted its holdings in shares of Amphastar Pharmaceuticals by 1.3% in the 2nd quarter. Northern Trust Corp now owns 480,049 shares of the company’s stock valued at $10,133,000 after purchasing an additional 6,260 shares during the last quarter. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

In other Amphastar Pharmaceuticals news, SVP Yakob Liawatidewi sold 1,515 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $21.24, for a total value of $32,178.60. Following the completion of the sale, the senior vice president now owns 36,670 shares in the company, valued at approximately $778,870.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO William J. Peters sold 9,800 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $21.76, for a total transaction of $213,248.00. Following the completion of the transaction, the chief financial officer now directly owns 92,253 shares in the company, valued at approximately $2,007,425.28. The disclosure for this sale can be found here. Insiders have sold a total of 323,155 shares of company stock valued at $6,742,840 in the last quarter. 30.80% of the stock is currently owned by corporate insiders.

Several equities research analysts recently issued reports on AMPH shares. BidaskClub raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, November 20th. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. TheStreet downgraded shares of Amphastar Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Thursday, November 7th. Finally, ValuEngine lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, September 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company’s stock. Amphastar Pharmaceuticals currently has an average rating of “Hold” and an average target price of $24.05.

AMPH stock opened at $19.51 on Monday. The company has a quick ratio of 1.84, a current ratio of 3.11 and a debt-to-equity ratio of 0.13. The firm has a 50 day moving average of $19.05 and a two-hundred day moving average of $20.28. The company has a market capitalization of $915.76 million, a price-to-earnings ratio of 47.58 and a beta of 1.16. Amphastar Pharmaceuticals Inc has a 12 month low of $16.71 and a 12 month high of $25.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.02. Amphastar Pharmaceuticals had a net margin of 15.77% and a return on equity of 5.07%. The firm had revenue of $80.14 million during the quarter, compared to the consensus estimate of $78.53 million. During the same period in the prior year, the firm earned $0.12 EPS. The business’s revenue was up 6.1% on a year-over-year basis. On average, research analysts expect that Amphastar Pharmaceuticals Inc will post 0.05 EPS for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Recommended Story: Technical Indicators – What is a Golden Cross?

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.